|
Market Closed -
Börse Stuttgart
15:56:13 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 96.65 EUR | +20.51% |
|
-0.19% | +8.89% |
| 08-19 | Moderna, Merck breakthrough could usher in wave of cancer vaccines | RE |
| 08-19 | US stock futures steady after tech slump; investors focus on Middle East tensions | RE |
| Market Cap | 19.99B 23.3B 18.66B 17.12B 32.2B 2,227B 32.73B 220B 86.23B 1,117B 87.48B 85.58B 3,693B | P/E 2026 * |
-17.6x | P/E 2027 * | -18.7x |
|---|---|---|---|---|---|
| Enterprise Value | 8.62B 10.05B 8.05B 7.38B 13.88B 960B 14.11B 94.95B 37.18B 482B 37.72B 36.9B 1,592B | EV / Sales 2026 * |
4.77x | EV / Sales 2027 * | 5.4x |
| Free-Float |
96.06% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioNTech SE
| 1 day | +20.51% | ||
| Current month | +8.89% | ||
| Current year | +8.89% |
| 3 years | 79.3 |  | 115.95 |
| 5 years | 79.3 | | 335 |
| 10 years | 11.5 | | 396.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Özlem Türeci
CTO | Chief Tech/Sci/R&D Officer | 59 | 2017-12-31 |
Ugur Sahin
CEO | Chief Executive Officer | 60 | 2008-06-01 |
| Director of Finance/CFO | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Helmut Jeggle
CHM | Chairman | 55 | 2008-06-01 |
| Director/Board Member | 69 | 2008-06-01 | |
| Director/Board Member | 65 | 2017-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +20.51% | -0.19% | - | - | 23.3B | |
| -1.90% | +2.37% | +69.11% | +110.88% | 73.45B | |
| +0.87% | +15.32% | +56.99% | +95.59% | 62.99B | |
| +1.71% | -1.22% | +2.71% | +501.29% | 28.05B | |
| -1.40% | +4.18% | +54.52% | +19.60% | 25.42B | |
| +21.96% | +21.98% | +1.54% | +2.50% | 23.3B | |
| +2.28% | +7.98% | +42.75% | -12.34% | 19.45B | |
| 0.00% | -4.11% | +243.99% | +423.83% | 18.16B | |
| -3.50% | -0.95% | +17.17% | +534.55% | 16.53B | |
| +2.39% | +7.96% | +44.96% | +157.77% | 13.16B | |
| Average | +4.29% | +5.90% | +59.31% | +203.74% | 31.17B | |
| Weighted average by Cap. | +3.08% | +6.61% | +58.12% | +168.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.81B 2.11B 1.69B 1.55B 2.91B 201B 2.96B 19.91B 7.8B 101B 7.91B 7.74B 334B | 1.84B 2.15B 1.72B 1.58B 2.97B 205B 3.02B 20.31B 7.95B 103B 8.07B 7.89B 341B |
| Net income | -1.35B -1.57B -1.26B -1.16B -2.17B -150B -2.21B -14.86B -5.82B -75.35B -5.9B -5.77B -249B | -1.31B -1.53B -1.23B -1.12B -2.12B -146B -2.15B -14.47B -5.67B -73.38B -5.75B -5.62B -243B |
| Net Debt | -11.37B -13.25B -10.62B -9.74B -18.32B -1,267B -18.62B -125B -49.05B -635B -49.76B -48.68B -2,101B | -10.03B -11.69B -9.37B -8.59B -16.16B -1,118B -16.43B -111B -43.28B -561B -43.91B -42.95B -1,853B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-19 | €96.65 | +20.51% | 46,226 |
| 26-08-18 | €80.20 | +1.20% | 1,812 |
| 26-08-17 | €79.25 | -1.55% | 746 |
| 26-08-14 | €80.50 | +0.88% | 1,182 |
| 26-08-13 | €79.80 | -0.87% | 7,314 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BNTX Stock
- 22UA Stock
Select your edition
All financial news and data tailored to specific country editions
